RAPT Board Member Receives $185K Worth of Stock Options in Annual Grant

Rhea-AI Filing Summary

RAPT Therapeutics director Scott Braunstein received a stock option grant on June 21, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:

• Grant of 25,000 stock options to purchase common stock
• Exercise price set at $7.43 per share
• Options expire on June 21, 2035
• Vesting schedule: Equal annual installments over three years from grant date

This equity compensation grant appears to be part of the company's standard director compensation program. The options were granted with direct ownership form, and the filing was submitted by attorney-in-fact Rodney Young on June 24, 2025. This transaction represents a new position for the director, as no prior holdings were reported in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Braunstein Scott

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$7.43	06/21/2025		A		25,000		(1)	06/21/2035	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The shares subject to the option shall vest in three successive equal annual installments over the three-year period measured from the date of grant of June 21, 2025.

	/s/ Rodney Young, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did RAPT Therapeutics director Scott Braunstein receive on June 21, 2025?

Scott Braunstein received 25,000 stock options with an exercise price of $7.43 per share. These options were granted on June 21, 2025, and will expire on June 21, 2035.

What is the vesting schedule for RAPT director Braunstein's stock options granted in June 2025?

The stock options will vest in three equal annual installments over a three-year period, starting from the grant date of June 21, 2025.

Who filed the Form 4 for RAPT Therapeutics (RAPT) on June 28, 2025?

The Form 4 was filed for Scott Braunstein, who serves as a Director of RAPT Therapeutics. The form was signed by Rodney Young as Attorney-in-Fact on June 24, 2025.

What is the total value of RAPT stock options granted to Scott Braunstein in June 2025?

Scott Braunstein received 25,000 stock options with an exercise price of $7.43 per share. The options were reported with a price of $0, as they were granted as part of director compensation and not purchased.

Did RAPT director Scott Braunstein make any direct stock purchases or sales in this Form 4 filing?

No, the Form 4 filing shows no direct purchases or sales of RAPT common stock. The only reported transaction was the grant of 25,000 stock options as part of director compensation.